Carrington Laboratories, Inc. said Southern Research Institute transferred its responsibilities under a one year renewal of two related agreements with Carrington's wholly owned subsidiary, DelSite Biotechnologies, Inc., to Brookwood Pharmaceuticals, Inc. of Birmingham, Alabama, a newly formed drug-delivery company. The agreements involve the development, formulation and ultimate commercialization of DelSite's patented drug-delivery technology based on the natural polymer GelSite.
Brookwood Pharmaceuticals was formed January 2005 as a spin out of Southern Research Institute's drug delivery group. The original agreements with Southern Research lasted three years and contemplated the current extension.
One of the key applications the technology is that aqueous-based formulations of GelSite(R) form a gel in situ after parenteral injection, making a depot that time releases proteins and peptides.
DelSite and Brookwood believe the technology holds the potential to deliver proteins and peptides, reducing the frequency of drug administration and improving patient compliance, as well as potentially increasing safety and efficacy.